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GmbObjectives: Cardiac surgery with cardiopulmonary bypass frequently leads to excessive bleeding, obligating
blood product transfusions. Because low factor XIII (FXIII) levels have been associated with bleeding after car-
diac surgery, we investigated whether administering recombinant FXIII after cardiopulmonary bypass would re-
duce transfusions.
Methods: In this double-blinded, placebo-controlled, multicenter trial, 409 cardiac surgical patients at moderate
risk for transfusion were randomized to receive an intravenous dose of recombinant FXIII, 17.5 IU/kg (n¼ 143),
35 IU/kg (n ¼ 138), or placebo (n ¼ 128) after cardiopulmonary bypass. Transfusion guidelines were standard-
ized. The primary efficacy outcome was avoidance of allogeneic blood products for 7 days postsurgery. Second-
ary outcomes included amount of blood products transfused and reoperation rate. Serious adverse events were
measured for 7 weeks.
Results: Study groups had comparable baseline characteristics and an approximately 40% decrease in FXIII
levels after cardiopulmonary bypass. Thirty minutes postdose, FXIII levels were restored to higher than the
lower 2.5th percentile of preoperative activity in 49% of the placebo group, and 85% and 95% of the 17.5-
and 35-IU/kg recombinant FXIII groups, respectively (P< .05 for both treatments vs placebo). Transfusion
avoidance rates were 64.8%, 64.3%, and 65.9% with placebo, 17.5 IU/kg, and 35 IU/kg recombinant FXIII
(respective odds ratios against placebo, 1.05 [95% confidence interval, 0.61-1.80] and 0.99 [95% confidence
interval, 0.57-1.72]). Groups had comparable adverse event rates.
Conclusions: Replenishment of FXIII levels after cardiopulmonary bypass had no effect on transfusion avoid-
ance, transfusion requirements, or reoperation in moderate-risk cardiac surgery patients (ClinicalTrials.gov
identifier: NCT00914589). (J Thorac Cardiovasc Surg 2013;146:927-39)Cardiac surgery requiring the use of cardiopulmonary by-
pass (CPB) is frequently complicated by coagulopathy.1
Timely control of the coagulopathy is essential if patients
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Perioperative Management Karkouti et al
P
Mof therapy for coagulopathy in the setting of cardiac surgery
includes antifibrinolytic drug therapy to prevent excessive
fibrinolysis, platelet transfusions to increase the number
of functioning platelets, and plasma transfusions to
replenish coagulation factor levels.1 These therapies, how-
ever, are frequently ineffective and are themselves associ-
ated with adverse outcomes.5-7 Thus, there remains a need
for novel therapies that can effectively and safely prevent
or treat coagulopathy after cardiac surgery.
Several plasma-derived and recombinant coagulation
factors are available for systemic administration, and their
hemostatic effectiveness is under clinical investigation.
One potential candidate is recombinant factor XIII (FXIII).
FXIII is the terminal enzyme in the coagulation cascade,
and is necessary for cross-linking of fibrin monomers to
form a stable and strong fibrin clot.8-10 Cardiac surgery
with CPB leads to a marked reduction in plasma FXIII
levels,11-16 and an association between low FXIII levels
and increased bleeding has been noted in cardiac surgery
and other clinical settings,12-17 but this finding is not
consistent.18 Recombinant FXIII has already undergone
preliminary clinical trials,19,20 and in cardiac surgery, it
has been well tolerated in doses from 11.9 to 50 IU/kg,
with 35 IU/kg suggested as possibly the most appropriate
dose for replenishment of FXIII levels after cardiac
surgery with CPB.20 In the current clinical trial, we assessed
the hemostatic efficacy of 2 doses of recombinant FXIII
(17.5 and 35 IU/kg) administered at the conclusion of
CPB in patients who were at moderate risk for requiring
perioperative transfusions due to blood loss to determine
whether such treatment would reduce transfusion needs.METHODS
This was a randomized, double-blinded, placebo-controlled, multina-
tional, multicenter, phase 2, dose-finding trial conducted from July 27,
2009, to February 23, 2011. The trial was performed in accordance with
the Declaration of Helsinki, International Conference on Harmonization
Good Clinical Practice, and was approved by the health authorities of
each of the countries involved and by the independent ethics committees
or institutional review boards of each center involved. All patients provided
written informed consent before involvement in the study. Details of the
centers are presented in Appendix 1. The trial was registered at http://
www.clinicaltrials.gov (identifier: NCT00914589).
Patients
Adult patients (aged 18-80 years) who were scheduled to undergo non-
emergent coronary artery bypass grafting requiring CPB, single heart valve
replacement or repair requiring CPB, or both of these surgical interventions
were eligible for inclusion. Intraoperative antifibrinolytic intervention was928 The Journal of Thoracic and Cardiovascular Surgmandatory, and patients were required to be at moderate risk for transfu-
sion. A moderate risk for transfusion was defined as meeting 2 or 3 of
the following criteria: (1) nonelective surgery, (2) redo surgery, (3) com-
bined coronary artery bypass grafting and valve surgery, (4) aged 69 years
or older, (5) body surface area lower than 1.9 m2, (6) creatinine level higher
than 100 mmol/L if female and 110 mmol/L if male, (7) platelet count lower
than 150,000/mL, and (8) hematocrit lower than 36% if female and 39% if
male.21,22 The validity of the criteria for identifying patients at moderate
risk for transfusion was confirmed at 2 of the participating centers before
trial initiation by retrospectively assessing the transfusion rates in
patients who would have met the inclusion criteria. FXIII levels were not
considered for inclusion of patients into the study.
Patients were excluded at screening if they had any of the following con-
ditions: history of coagulation disorders, autoimmune diseases, thrombo-
embolic events (excluding cardiac), stroke, or ST-elevated myocardial
infarction within 7 days of surgery; received adenosine diphosphate recep-
tor antagonists within 3 days of surgery, glycoprotein IIb/IIIa receptor
blockers within 24 hours of surgery, low-molecular-weight heparin within
24 hours of surgery, or vitamin K antagonist therapy accompanied by an
international normalized ratio higher than 1.5 on the day of surgery; weight
of 140 kg or higher; left ventricular ejection fraction lower than 30%; liver
dysfunction (aspartate aminotransferase or alanine aminotransferase level
>2-fold higher than the upper limit of normal); platelet count lower than
1003 109/L; creatinine level of 175 mmol/L or higher or receiving dialysis;
and hematocrit predicted to be lower than 27% during CPB (based on start-
ing hematocrit and CPB prime volume).
Eligibility for trial drug administration was reevaluated 15 minutes after
initiation of protamine dosing for reversal of heparin, and patients were ex-
cluded before trial drug administration (but after randomization) if they had
received any blood products or fibrin sealants. In addition, patients were ex-
cluded if they had a hematocrit lower than 22% before cross-clamp removal
(because theywould have a high chance of receiving packed red blood cells
irrespective of the amount of post-CPB blood loss) or had experienced any
of the following factors that would have changed their transfusion risk from
moderate to high: CPB duration longer than 3 hours, surgery on the aortic
arch or descending aorta, hypothermic (<28C) circulatory arrest, or severe
hemodynamic instability after CPB that may have necessitated reinstitution
of CPB. Patients were also excluded if the trial drug could not be adminis-
tered within 30 minutes of protamine administration.
Trial Drug Administration
Eligible patients were randomized (1:1:1) using an interactive voice/
Web response system to a single intravenous dose of 17.5 or 35 IU/kg (ac-
cording to lean body mass) of recombinant FXIII or placebo before the in-
duction of anesthesia. Randomization was stratified according to trial site,
transfusion risk score (2 or 3), age group (<65 or 65 years), and whether
the patient had undergone previous cardiac surgery. The appearance and
physical properties of recombinant FXIII and placebo were indistinguish-
able. Study drug/placebo was administered via a slow intravenous push
(2 mL/min) at 15 to 30 minutes after initiation of protamine dosing after
CPB but before any other hemostatic therapies. Induction of anesthesia,
dosing with heparin and protamine (to induce and subsequently reverse an-
ticoagulation), and administration of antifibrinolytic treatment (tranexamic
acid) were performed according to standard clinical practice at each site.TRANSFUSION MANAGEMENT
Autologous blood collected before surgery and acute nor-
movolemic hemodilution were not permitted. Any shed
blood collected in the operating room could be retransfused,
washed or unwashed, depending on institutional practice.
Retransfusion of blood collected in mediastinal drains
was not permitted.ery c October 2013
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MPerioperative transfusion practice was standardized. Red
blood cell transfusion was mandatory for hemoglobin lower
than 6.0 g/dL, optional for hemoglobin between 6.0 and 8.0
g/dL, acceptable for hemoglobin between 8.0 and 10.0 g/dL
(provided there was evidence for end-organ ischemia), and
not permitted for higher hemoglobin values. Transfusions
were to be administered 1 U at a time, and the hemoglobin
had to be rechecked after each unit. Coagulation products
were to be administered if, after reversal of protamine, pa-
tients bled 2 mL/kg or more over 30 minutes or 1.5 mL/kg
or more per hour over 2 consecutive hours. Fresh-frozen
plasma (10-15 mL/kg) was to be administered if the interna-
tional normalized ratio was 1.5 or higher. Platelets (1 apher-
esis unit or 4-6 pooled units) were to be transfused if the
platelet count was 100 3 109/L or lower. Fibrinogen con-
centrate (2 g) or cryoprecipitate (8-10 U) was to be trans-
fused if the fibrinogen concentration was 1.5 g/L or lower.
An external adjudication committee was established to en-
sure compliance with the transfusion protocol at each
center.
LABORATORY TESTS
Blood sampling for clinical laboratory tests was per-
formed before surgery, after protamine, but before trial
drug administration, and at the following times after trial
drug administration: 30  5 minutes, 8  0.5 hours, 24 
2 hours, 48  6 hours, 72  6 hours, 7 days or discharge,
and 5 to 7 weeks. Standard laboratory tests (hematology, co-
agulation parameters, biochemistry, and urinalysis) were
performed by a local laboratory. Specialty laboratory as-
sessments were performed by a central laboratory; these in-
cluded FXIII activity (FXIII Berichrom activity assay),
FXIII B-subunit (enzyme-linked immunosorbent assay),
prothrombin fragment 1 þ 2, troponin T, fibrinogen, fibrin
monomers, and recombinant FXIII antibodies (direct
FXIII-antibody enzyme-linked immunosorbent assay).
Pharmacodynamic and Pharmacokinetic Outcomes
Pharmacodynamic and pharmacokinetic outcomes in-
cluded plasma FXIII activity levels and the restoration of
plasma FXIII activity to higher than the lower 2.5th percen-
tile of the distribution of preoperative activity.
Efficacy Outcomes
The primary efficacy end point was the percentage of pa-
tients avoiding any allogeneic transfusions (red blood cell,
fresh-frozen plasma, platelets, cryoprecipitate, or fibrino-
gen concentrate) up to postoperative day 7 or hospital dis-
charge, whichever came first. Secondary efficacy end
points, which were also assessed up to postoperative day
7 or hospital discharge, were the amount (units) of trans-
fused blood products, the percentage of patients avoiding
any red blood cell transfusion, and the percentage of pa-
tients avoiding massive red blood cell transfusion (5 U).The Journal of Thoracic and CaThe incidence of reoperation was assessed until the end of
the trial.
Safety
An external, independent safety data monitoring commit-
tee (Appendix 2) was established to ensure the safety of pa-
tients. All adverse events (AEs), including severity, relation
to trial product, and patient outcome, were reported from
the time of trial drug administration until postoperative
day 7 or hospital discharge. For serious AEs, reporting con-
tinued until the follow-up visit at 5 to 7 weeks after trial
drug administration. Prespecified critical AEs were throm-
boembolic events (including acute myocardial infarction
[based on enzyme and electrocardiographic criteria, which
were evaluated by an independent central laboratory],
stroke, or transient ischemic attack, peripheral artery occlu-
sion, deep venous thrombosis, and pulmonary embolism),
renal dysfunction (doubling of creatinine or renal replace-
ment therapy), reoperation, and death.
Statistical Analysis
The sample size of 409 patients (136 per group) was
based on the following assumptions: transfusion avoidance
rate of 40% in the placebo arm (based on the validation of
the transfusion risk criteria) and 55% in each of the treat-
ment arms, 70% power, and a level of .05 (2 sided). The
null hypothesis was that placebo and recombinant FXIII ad-
ministration resulted in the same avoidance rate (ie, odds ra-
tio, 1).
Except where noted, all statistical analyses, including co-
variate selection, were planned a priori. Transfusion avoid-
ance rates were compared between treatment groups using
logistic regression analysis, adjusting for the following co-
variates: trial site, transfusion risk score (2 or 3), age group
(<65 or 65 years), previous cardiac surgery, pretrial drug
administration fibrinogen level, pretrial drug administration
platelet count, urgency of surgery, and treatment arm. In
sensitivity analyses, the primary analysis was repeated, ad-
justing only for statistically significant covariates and with-
out adjusting for any covariates.
A blinded data review showed that the distribution of the
amount of transfusions was not consistent with a Poisson
distribution (ie, most patients did not receive any transfu-
sions, and a few patients received many units, with 1 receiv-
ing >80 U). Therefore, the amount of transfusions was
compared using a cumulative logit model on 0, 1, 2, 3, 4,
and>4 U. This analysis was adjusted for covariates, as
for the primary analysis.
The proportion of patients whose plasma FXIII activity
level was restored to higher than the lower 2.5th percentile
of the distribution of preoperative activity level was also
compared between treatment groups using logistic regres-
sion analysis, adjusting for transfusion risk score (2 or 3),
age, pretrial drug administration FXIII plasma activity,rdiovascular Surgery c Volume 146, Number 4 929
Perioperative Management Karkouti et al
P
Mand treatment. The plasma concentration of FXIII at each
time point was compared among treatment groups using
analysis of variance, adjusting for these covariates.
The impact of the achieved FXIII activity level on the
avoidance of any transfusions was analyzed in a manner
analogous to the primary analysis, except that ‘‘treatment’’
was replaced by FXIII plasma activity at 30 min, 24 h, and
48 h in the respective analyses. The interaction effect be-
tween predose FXIII activity and treatment on avoidance
of allogeneic transfusions was analyzed in a model similar
to the primary analysis, but with predose FXIII activity as
a covariate both on its own and in interaction with
treatment.
The rate of critical AEs was compared between treatment
groups using logistic regression analysis, adjusting for
transfusion risk score (2 or 3), age, type of surgery (elective
vs nonelective), and treatment.
The trial was sponsored by Novo Nordisk A/S (Bags-
værd, Denmark). The authors designed the trial protocol,
directed the statistical plan, and wrote the manuscript.
The sponsor oversaw the trial operations, audited all
data, and conducted the statistical analyses. Dr KarkoutiFIGURE 1. Patient disposition. rF
930 The Journal of Thoracic and Cardiovascular Surgsigned the clinical trial report, and the authors had full ac-
cess to and take full responsibility for the integrity of the
data. All authors have read and agree with the manuscript
as written.
RESULTS
Patient Disposition, Demographics, and Operative
Details
Patient disposition is shown in Figure 1. Of the 479 ran-
domized patients, 409 were eligible to receive study drug
and were included in the analyses. Within this group, 128
received placebo, 143 received 17.5 IU/kg of recombinant
FXIII, and 138 received 35 IU/kg of recombinant FXIII.
A total of 356 patients completed the entire trial, including
the 5- to 7-week postoperative visit.
The 13 European hospitals randomized 61% of patients,
followed by the 5 Canadian hospitals (28%), 7 US hospitals
(5%), 4 Japanese hospitals (4%), and 2 Israeli hospitals
(2%) (Appendix 1). This variability is, in part, the result
of the study being initiated first in Europe, followed by Can-
ada, and then in the other countries. Patients had similar
characteristics, baseline laboratory values, and operativeXIII, Recombinant factor XIII.
ery c October 2013
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had a transfusion risk score of 2 or 3.
FXIII Activity Levels
Baseline FXIII activity levels were similar across treat-
ment groups (Table 1). In addition, all 3 groups had an ap-
proximately 40% decrease in FXIII levels after CPB
(Figure 2). Administration of recombinant FXIII increased
FXIII levels in a dose-dependent manner, and the levels re-
mained higher than in the placebo group across all 7-day
postoperative time points (Figure 2). The proportion of pa-
tients who, at 30 minutes postdose, had achieved restoration
of FXIII activity to higher than the lower 2.5th percentile of
the preoperative activity was 49% in the placebo group,
85% in the 17.5-IU/kg recombinant FXIII group, and
95% in the 35-IU/kg recombinant FXIII group (P<.05 in
both treatment groups vs placebo).
Efficacy Outcomes
The administration of recombinant FXIII had no effect on
allogeneic transfusion avoidance (Table 2). The proportion
of patients who avoided transfusion was 64.8% with pla-
cebo versus 64.3% with recombinant FXIII, 17.5 IU/kg,TABLE 1. Patient characteristics and operative details
Placebo (n ¼
Patient characteristics at screening
Age, mean (SD), y 69 (9)
Male sex, no. (%) 100 (78.1
White race, no. (%) 117 (91.4
Body surface area, mean (SD), m2 1.9 (0.2)
Left ventricular ejection fraction, mean (SD),% 56 (10)
Baseline assessments before anesthesia*
Hemoglobin, mean (SD), g/dL 13.7 (1.3)
Creatinine, mean (SD), mmol/L 88 (22)
Platelet count, mean (SD), 3109/L 210 (63)
INR, mean (SD) 1.1 (0.1)
Fibrinogen, mean (SD), mg/dL 406 (129)
FXIII activity, mean (SD), IU/mL 1.23 (0.26
FXIII B-subunit, mean (SD), mg/mL 4.71 (1.65
Operative details
CABG, no. (%) 56 (43.8
Valve repair or replacement, no. (%) 39 (30.5
Combined CABG and valve, no. (%) 33 (25.8
Redo surgery, no. (%) 6 (4.7)
Nonelective surgery, no. (%) 33 (25.8
EuroSCORE, mean (SD) 4.3 (2.1)





rFXIII, Recombinant factor XIII; INR, international normalized ratio; CABG, coronary ar
(preinduction). If data were not available, data from the screening visit were used. ySee M
The Journal of Thoracic and Caand 65.9% with recombinant FXIII, 35 IU/kg. This trans-
lated to an odds ratio close to unity for the comparisons
of active treatments against placebo in the applied logistic
regression analysis (1.05 [95% confidence interval, 0.61-
1.80] for the 17.5-IU/kg recombinant FXIII group and
0.99 [95% confidence interval, 0.57-1.72] for the 35-IU/
kg recombinant FXIII groups). Although transfusion prac-
ticewas protocolized and there were few protocol violations
(n ¼ 30), transfusion rates varied substantially across sites;
the median rate was 29%, and the 25th and 75th percentiles
were 24% and 50% (sites with 3 randomized patients
were considered a single site for this calculation), with
a transfusion rate of 30%. Trial site (P ¼ .0001) was the
most important determinant of transfusion avoidance. The
results of sensitivity analyses were similar to those of the
main analysis.
Subgroup and interaction analyses showed no effect of
recombinant FXIII on transfusion avoidance in any of the
analyzed subgroups defined by predose FXIII activity, pre-
dose fibrinogen concentration, transfusion risk marker, and
type of surgery. No interaction between treatment and pre-
dose FXIII activity level was identified from logistic regres-
sion analysis of transfusion avoidance (P ¼ .60).128)
rFXIII rFXIII
17.5 IU/kg (n ¼ 143) 35 IU/kg (n ¼ 138)
69 (9) 69 (8)
) 119 (83.2) 117 (84.8)
) 129 (90.2) 125 (90.6)
1.9 (0.2) 1.9 (0.2)
57 (11) 56 (9)
13.6 (1.3) 13.7 (1.2)
90 (23) 93 (22)
210 (61) 212 (57)
1.1 (0.1) 1.1 (0.1)
401 (138) 426 (148)
) 1.14 (0.28) 1.20 (0.29)
) 4.91 (1.88) 4.80 (1.92)
) 79 (55.2) 79 (57.2)
) 36 (25.2) 36 (26.1)
) 28 (19.6) 23 (16.7)
3 (2.1) 11 (8.0)
) 44 (30.8) 44 (31.9)
4.1 (2.0) 4.3 (2.1)
2 (1.4) 1 (0.7)
82 (57) 88 (64)
57 (40) 48 (35)
2 (1.4) 1 (0.7)
tery bypass grafting. *Baseline values were collected before induction of anesthesia
ethods for list of risk factors.
rdiovascular Surgery c Volume 146, Number 4 931
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FIGURE 2. Factor XIII levels. Data shown are means and SDs. rFXIII, Recombinant factor XIII; TDA, trial drug administration.
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MFurthermore, there was no impact of FXIII activity level at
30 minutes postdose on avoidance of allogeneic transfusion
(P ¼ .64).
For the secondary transfusion end points, administration
of recombinant FXIII did not reduce transfusion require-
ments, massive red blood cell transfusions, or the incidence
of reoperation.
Safety
Administration of recombinant FXIII was not associated
with an increased rate of AEs versus placebo, including all
AEs, serious AEs, AEs possibly or probably related to study
medication, and withdrawals due to AEs (Table 3). The
most commonly reported AEs were pleural effusion
(37%), atrial fibrillation (35%), procedural pain (30%),
nausea (29%), anemia (17%), peripheral edema (16%),
and hypotension (16%). Most AEs were mild or moderateTABLE 2. Efficacy outcomes*
Pla
Patients who avoided allogeneic transfusions, no. (%)
All transfusions
Red blood cell transfusions
Massive (5 U) red blood cell transfusion
Units of transfused blood products, median (25th, 75th percentiles)
Incidence of reoperation, no. (%)
rFXIII, Recombinant factor XIII. *None of the prespecified comparisons was statistically
932 The Journal of Thoracic and Cardiovascular Surgin severity. More important, thromboembolic and prede-
fined critical AEs occurred with similar frequencies in the
FXIII and placebo groups. There were 2 fatal AEs (myocar-
dial infarction and sepsis), which both occurred during
FXIII treatment but were considered unlikely to be related
to trial drug. None of the patients developed antibodies to
recombinant FXIII.
DISCUSSION
In this randomized, double-blinded, placebo-controlled,
multicenter clinical trial, we measured the hemostatic effi-
cacy of 17.5 and 35 IU/kg of recombinant FXIII adminis-
tered at the conclusion of CPB to patients who were at
moderate risk for requiring perioperative transfusions be-
cause of blood loss. We found that FXIII levels were re-
duced by approximately 40% after CPB. We also found
that, although both doses of recombinant FXIIIcebo (n ¼ 128)
rFXIII rFXIII
17.5 IU/kg (n ¼ 143) 35 IU/kg (n ¼ 138)
83 (64.8) 92 (64.3) 91 (65.9)
85 (66.4) 94 (65.7) 92 (66.7)
125 (97.7) 140 (97.9) 136 (98.6)
0 (0, 1) 0 (0, 1) 0 (0, 1)
2 (1.6) 8 (5.6) 4 (2.9)
significant.
ery c October 2013
TABLE 3. Adverse events*
Placebo (n ¼ 128)
rFXIII rFXIII
17.5 IU/kg (n ¼ 143) 35 IU/kg (n ¼ 138)
All AEs 126 (98.4) 139 (97.2) 135 (97.8)
Serious AEs 35 (27.3) 43 (30.1) 32 (23.2)
AEs by severity
Severe 24 (18.8) 31 (21.7) 23 (16.7)
Moderate 91 (71.1) 93 (65.0) 77 (55.8)
Mild 111 (86.7) 120 (83.9) 119 (86.2)
AEs probably/possibly related to study drug
All 14 (10.9) 17 (11.9) 15 (10.9)
Serious AEs 5 (3.9) 6 (4.2) 4 (2.9)
Withdrawals due to AEs 1 (0.8) 1 (0.7) 1 (0.7)
Thromboembolic events 12 (9.4) 12 (8.4) 9 (6.5)
Perioperative acute myocardial infarction 8 (6.3) 10 (7.0) 7 (5.1)
Cerebrovascular thromboembolic event 3 (2.3) 2 (1.4) 0
Deep vein thrombosis 1 (0.8) 0 1 (0.7)
Peripheral artery occlusion 0 0 1 (0.7)
Pulmonary embolism 0 0 0
Prespecified critical AEs 19 (14.8) 24 (16.8) 16 (11.6)
Thromboembolic events 12 (9.4) 12 (8.4) 9 (6.5)
Renal dysfunction 9 (7.0) 10 (7.0) 5 (3.6)
Reoperation 2 (1.6) 8 (5.6) 4 (2.9)
Death 0 1 (0.7) 1 (0.7)
Results are reported as number (%), where number indicates patients with an AE. rFXIII, Recombinant factor XIII; AE, adverse event. *None of the prespecified comparisons was
statistically significant.
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Msignificantly increased post-CPB FXIII levels, they had no
effect on any of the efficacy end points, in either the entire
sample or the subset of patients who had low predose
FXIII activity. No safety issues were identified, because
AEs were evenly distributed across treatment groups and
individual types of AEs, including thromboembolic AEs
and events predefined as critical for the trial, did not occur
with higher frequency in the active dose groups relative to
placebo.
The finding that FXIII levels are substantially reduced af-
ter CPB is consistent with those of previous studies, which
have generally found there is approximately a 40% de-
crease in FXIII levels from baseline to after CPB.11-16
Although other coagulation factor levels decrease by
similar amounts, our hypothesis was based on several
lines of evidence that suggest that FXIII substitution after
CPB may reduce blood loss. First, several observational
studies have found an inverse correlation between FXIII
levels after CPB and clot strength or blood loss,12-16 but
this finding is not consistent.18 Second, soluble fibrin mono-
mer levels are increased after CPB, and this increase is in-
dependently associated with increased blood loss.11 In the
presence of adequate FXIII levels, soluble fibrin monomers
are cross-linked into stable, insoluble fibrin clots.23 Thus,
the observed accumulation of soluble fibrin monomers after
CPB suggests that there is a relative deficiency of FXIII
levels that may contribute to inadequate clot formation
and increased bleeding. Third, preliminary studies haveThe Journal of Thoracic and Cashown that FXIII substitution is associated with improved
clot strength and reduced blood loss.12,14,24
Nevertheless, this study’s finding suggests that, at least in
patients undergoing moderate-risk cardiac surgery and re-
ceiving concomitant antifibrinolytic drug therapy, replen-
ishment of FXIII levels at the conclusion of CPB with
recombinant FXIII does not reduce transfusion rates. To
our knowledge, 2 other studies have explored the efficacy
of FXIII replacement in cardiac surgery.12,14 One study
included 22 consecutive patients who underwent low-risk
cardiac surgery and were alternately assigned to control
or FXIII arms (who received 2500 U of FXIII postopera-
tively).12 In that study, patients who received FXIII had
lower blood loss and transfusion rates, but only the former
achieved statistical significance, and patients were not prop-
erly randomized.12 More recently, the same group conduct-
ed another trial that included 75 patients who underwent
low-risk cardiac surgery and were randomized to placebo,
low-dose (1250 U), or high-dose (2500 U) FXIII postoper-
atively (25 patients in each group).14 In this blinded study,
the amounts of blood loss and transfusion were highest in
the placebo group and lowest in the high-dose group, but
none of the between-group differences achieved statistical
significance.14 In both of these studies, patients received
concomitant antifibrinolytic therapy (aprotinin), but the
transfusion protocol was not standardized.
Several characteristics of this study must be considered
when interpreting its negative results. First, based on therdiovascular Surgery c Volume 146, Number 4 933
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Mrequirements of some drug-regulating agencies, it was
deemed necessary to determine if FXIII replenishment re-
sulted in increased transfusion avoidance. As a result, the
sample was limited to patients in whom there was a reason-
able chance of transfusion avoidance, which (based on our
inclusion criteria) placed them at moderate risk for transfu-
sion. Moreover, despite validating the inclusion criteria at 2
of the participating centers, the transfusion avoidance rate
was higher than anticipated, indicating that the transfusion
risk in the sample was lower than anticipated. Second, the
decision was made to determine the efficacy of FXIII
when it is administered early after CPB, irrespective of
FXIII levels. Third, the drug was tested in the context of
concomitant antifibrinolytic therapy. Thus, it is possible
that the drug may have better efficacy in patients whose
transfusion risk is higher, in those with severe (<20%-
30% activity levels) FXIII deficiency after CPB, or in place
of antifibrinolytic drugs. Because FXIII is the terminal en-
zyme in the coagulation cascade,8-10 targeting coagulation
factors involved in the earlier stages of coagulation, such
as fibrinogen, may be more effective.25 Adequately pow-
ered randomized controlled trials are needed to examine
these issues.
Although this study had many strengths (large, multicen-
ter, placebo-controlled, blinded, randomized trial), it had 2
important weaknesses. First, because this was a phase 2
study, it was not adequately powered to prove drug safety
and was only 70% powered for efficacy. Nevertheless, the
efficacy results were clear and there were no major safety
concerns detected. Second, despite attempts to standardize
transfusion therapy, there were significant variations in
transfusion rates across the sites. The reasons for these var-
iations are unclear, but because randomization was stratified
according to the site, it is unlikely that this limitation led to
unmeasured biases.
In summary, in this multicenter, double-blinded, placebo-
controlled, randomized trial, we found that administration
of recombinant FXIII (17.5 or 35 IU/kg) after cardiac sur-
gery and CPB in patients at moderate risk for transfusion re-
stored FXIII activity to preoperative levels but had no
hemostatic benefits, as measured by transfusion avoidance,
transfusion requirements, or need for reoperation.
Editorial assistance to the authors during the preparation of the
manuscript was provided by Anne Stirland, PhD (medical writer,
PAREXEL).
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